Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Pramipexole Slow-release Formulations vs Immediate-release
NCT02261090Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2004
- Primary completion
- Sep 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of pramipexole in Parkinson's disease (PD) (8 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Plasma total exposure (AUCtau,ss), Urine total exposure (Aetau,ss) and 4 more. Started Jun 2004; status: completed.
02
Drugs
pramipexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02261090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261090.